Study supports the potential benefits of screening patients for CHIP before they undergo cancer treatment so they can be more closely monitored for heart complications.
The findings could lead to new treatments for blood cancers, which kill an estimated 23,540 people in the United States every year.
The analysis of genetic sequencing data from more than 34,000 people over a 17-year period by researchers at VUMC was published in eClinicalMedicine.
They are among more than 3,500 ASCI members, 48 of whom are current, full-time faculty members of the Vanderbilt University School of Medicine.
Research could lead to improved diagnosis and the first effective treatment for the disorder, called “clonal hematopoiesis of indeterminate potential,” or CHIP.
Bick will succeed Nancy Cox, PhD, who has led Genetic Medicine since she came to VUMC in 2015. Genetic Medicine is one of 13 divisions in the Department of Medicine.